SCHEDULE Filed 2025-03-10 Event 2025-03-06 SEC 0001415889-25-007529 →

RA CAPITAL MANAGEMENT, L.P. → Janux Therapeutics, Inc. JANX

Stake: 19.90% Shares: 11,971,377 CUSIP: 47103J105 Class: Common Stock, par value $0.001 per share

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

1 transaction

0 buys · 0 sales · 1 awards/exercises

Issuer Cluster

2 13D/G filings on this issuer

1 other filing besides this one

Filer Track Record

83 filings by this filer

82 other filings in the data moat

Short Interest · settle 2026-08-31

DTC 7.81

6,063,535 shares short · -8.5% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $13.27M

Point72 Asset Mgmt

Post-Filing Returns · since 2025-03-06 on JANX

+1 day

0.0%

+5 days

0.0%

+30 days

0.0%

+60 days

0.0%

+90 days

0.0%

+180 days

0.0%

Anchor price 16.15 on closest trading day on/after 2025-03-06. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-07-08	Campbell David Alan	director, officer	Option exercise	7,000	$4.21	$29K

Other 13D/G Filings on Janux Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2024-10-25	SC	Avalon Ventures XI, L.P.	—	—	view →

Other Filings by RA CAPITAL MANAGEMENT, L.P.

Filed	Form	Issuer	Stake	Shares
2026-09-03	SCHEDULE 13G	JATT III Acquisition Corp	—	—	view →
2026-08-17	SCHEDULE 13G	Latigo Biotherapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13D/A	SEPTERNA, INC.	—	5,525,324	view →
2026-08-11	SCHEDULE 13D/A	Wave Life Sciences, Inc.	—	34,314,406	view →
2026-08-10	SCHEDULE 13D/A	SAB Biotherapeutics, Inc.	—	9,609,852	view →
2026-07-23	SCHEDULE 13D/A	ARTIVA BIOTHERAPEUTICS, INC.	—	18,415,956	view →
2026-07-22	SCHEDULE 13D/A	Freenome, Inc.	—	15,367,270	view →
2026-07-21	SCHEDULE 13D/A	VOR BIOPHARMA INC.	—	12,937,855	view →
2026-07-20	SCHEDULE 13G	Agenus Inc.	—	—	view →
2026-07-07	SCHEDULE 13D/A	Climb Bio, Inc. CLYM	33.00%	23,249,186	view →
2026-07-02	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	4.10%	1,985,541	view →
2026-06-26	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	6.00%	2,915,742	view →
2026-06-24	SCHEDULE 13D/A	SOLID BIOSCIENCES INC. SLDB	—	12,036,126	view →
2026-06-22	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	—	3,654,307	view →
2026-06-18	SCHEDULE 13D	Parabilis Medicines, Inc. PBLS	23.80%	28,933,371	view →
2026-06-15	SCHEDULE 13D/A	ARTIVA BIOTHERAPEUTICS, INC. ARTV	36.60%	17,811,623	view →
2026-06-15	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	—	5,138,703	view →
2026-06-03	SCHEDULE 13G	Editas Medicine, Inc. EDIT	—	—	view →
2026-05-21	SCHEDULE 13G	Sana Biotechnology, Inc. SANA	—	—	view →
2026-05-14	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	—	6,116,140	view →

Showing 20 of 82

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →